Abstract
Background: Malignant tumor is still one of the important diseases worldwide, cytotoxic CD8+ T lymphocytes (CTLs) play an important role in killing tumor cells.
Objective: To enhance the immune response of our previously identified HLA-A2-restricted CTL epitopes, we designed a multiepitope YL66. Method: The fusion protein GST-YL66 and DNA vaccine pcDNA3.1(+)-YL66 were used to induce CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*02+ healthy donors and and in HLA-A2.1/Kb transgenic(Tg) mice. and the activity of induced CTLs were tested by IFN-γ relesde ELISPOT assay and LDH cytotoxicity assay. Results: GST-YL66 induced CTL could lysis tumor cells and release IFN-γ both in vitro and in vivo, and pcDNA3.1(+)-YL66 could also induce significant CTL response in vivo. Conclusion: The designed fusion multiepitope YL66 could be used as a vaccine against patients with tumors expressing COX-2 and/or MAGE-4.Keywords: Cytotoxic T lymphocytes, vaccine, cancer immunotherapy, HLA-A2, epitope, YL66.
Protein & Peptide Letters
Title:A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo
Volume: 24 Issue: 6
Author(s): Yahong Wu, Wenjie Zhai, Meng Sun, Zhe Zou, Xiuman Zhou, Guodong Li, Zhongyi Yan, Yuanming Qi*Yanfeng Gao*
Affiliation:
- School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001,China
- School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001,China
Keywords: Cytotoxic T lymphocytes, vaccine, cancer immunotherapy, HLA-A2, epitope, YL66.
Abstract: Background: Malignant tumor is still one of the important diseases worldwide, cytotoxic CD8+ T lymphocytes (CTLs) play an important role in killing tumor cells.
Objective: To enhance the immune response of our previously identified HLA-A2-restricted CTL epitopes, we designed a multiepitope YL66. Method: The fusion protein GST-YL66 and DNA vaccine pcDNA3.1(+)-YL66 were used to induce CTLs from human peripheral blood mononuclear cells (PBMCs) of HLA-A*02+ healthy donors and and in HLA-A2.1/Kb transgenic(Tg) mice. and the activity of induced CTLs were tested by IFN-γ relesde ELISPOT assay and LDH cytotoxicity assay. Results: GST-YL66 induced CTL could lysis tumor cells and release IFN-γ both in vitro and in vivo, and pcDNA3.1(+)-YL66 could also induce significant CTL response in vivo. Conclusion: The designed fusion multiepitope YL66 could be used as a vaccine against patients with tumors expressing COX-2 and/or MAGE-4.Export Options
About this article
Cite this article as:
Wu Yahong, Zhai Wenjie , Sun Meng , Zou Zhe, Zhou Xiuman , Li Guodong, Yan Zhongyi , Qi Yuanming *, Gao Yanfeng *, A Novel Recombinant Multi-Epitope Vaccine Could Induce Specific Cytotoxic T Lymphocyte Response In Vitro and In Vivo, Protein & Peptide Letters 2017; 24 (6) . https://dx.doi.org/10.2174/0929866524666170419152700
DOI https://dx.doi.org/10.2174/0929866524666170419152700 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxicophoric and Metabolic In Silico Evaluation of Benzimidazole and Phenylbenzamide Derivatives with Potential Application as Anticancer Agents
Drug Metabolism Letters TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Cannabinoids in Energy Balance and Prospectives in the Therapy of Obesity
Current Medicinal Chemistry - Central Nervous System Agents Nutritional Metabolomics: Lessons from Companion Animals
Current Metabolomics Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention
Current Cancer Drug Targets Cyanidin 3-O-Glucoside Induces the Apoptosis in the Osteosarcoma Cells through Upregulation of the PPARγ and P21: An <i>In Vitro</i> Study
Anti-Cancer Agents in Medicinal Chemistry Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Naringenin and Ellagic Acid Reduce Tetrazolium Salt in the Absence of Cells
The Natural Products Journal RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry Meet Our Editor:
Current Enzyme Inhibition Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Mucoadhesive Nanoparticulate System for Oral Drug Delivery: A Review
Current Drug Therapy Screening Methods for Antioxidants-A Review
Mini-Reviews in Medicinal Chemistry Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Enteric Coated Guar Gum Microspheres of Ornidazole for Colonic Delivery
Current Nanoscience Essential Polymers Helping Patients with Obesity
Current Applied Polymer Science